Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity
Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity
复制标题
DOI：
10.1016/s0264-410x(02)00215-3
复制
发表时间：
2002-06-21
期刊：
影响因子：
5.5
通讯作者：
Payne, LG
中科院分区：
文献类型：
--
作者：
Chen, DX;Endres, RL;Payne, LG
将无毒霍乱毒素B亚基(CTB)和减毒(LTR72)或无毒(LTK63)的大肠杆菌不耐热毒素突变蛋白(LTK63)作为佐剂进行流感疫苗表皮粉末免疫(EPI)。当由EPI注射时，CTB、LTR72和LTK63在小鼠模型中显著增强了对流感疫苗的抗体反应和对致命攻击的保护。抗原剂量可以减少到原来的1/125。这些佐剂在EPI后的局部和全身耐受性良好。这些结果表明，流感疫苗和无毒细菌肠毒素的计划免疫有望用于人类疫苗接种。(C)2002爱思唯尔科学有限公司。保留所有权利。
The non-toxic B subunit of cholera toxin (CTB) and E. coli heat-labile toxin mutant proteins with reduced toxicity (LTR72) or no toxicity (LTK63) were used as adjuvants for epidermal powder immunization (EPI) with an influenza vaccine. When administered by EPI, CTB, LTR72 and LTK63 significantly augmented antibody responses to the influenza vaccine and protection against a lethal challenge in a mouse model. The antigen dose could be reduced by 125-fold. These adjuvants were well-tolerated both locally and systemically following EPI. These results suggest that EPI with influenza vaccine and a non-toxic bacterial enterotoxin hold promise for human vaccination. (C) 2002 Elsevier Science Ltd. All rights reserved.